154 related articles for article (PubMed ID: 20424627)
21. Comparison of recombinant human erythropoietin and darbepoetin alpha in children.
Can C; Emre S; Bilge I; Yilmaz A; Şirin A
Pediatr Int; 2013 Jun; 55(3):296-9. PubMed ID: 23461764
[TBL] [Abstract][Full Text] [Related]
22. Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease.
Hudson JQ; Sameri RM
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):141S-149S. PubMed ID: 12222584
[TBL] [Abstract][Full Text] [Related]
23. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
Singh AK
J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
[No Abstract] [Full Text] [Related]
24. New oversight put in place for physicians giving anemia drugs to patients with cancer.
Mitka M
JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885
[No Abstract] [Full Text] [Related]
25. Darbepoetin alfa for treatment of anaemia in a case of chronic renal failure during pregnancy--case report.
Ghosh A; Ayers KJ
Clin Exp Obstet Gynecol; 2007; 34(3):193-4. PubMed ID: 17937101
[TBL] [Abstract][Full Text] [Related]
26. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
Li WY; Chu TS; Huang JW; Wu MS; Wu KD
J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
[TBL] [Abstract][Full Text] [Related]
27. Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease.
Warady BA; Arar MY; Lerner G; Nakanishi AM; Stehman-Breen C
Pediatr Nephrol; 2006 Aug; 21(8):1144-52. PubMed ID: 16724235
[TBL] [Abstract][Full Text] [Related]
28. Overview of cancer-related anemia: focus on the potential role of darbepoetin alfa.
Valley AW
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):150S-159S. PubMed ID: 12222585
[TBL] [Abstract][Full Text] [Related]
29. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
Solomon SD; Uno H; Lewis EF; Eckardt KU; Lin J; Burdmann EA; de Zeeuw D; Ivanovich P; Levey AS; Parfrey P; Remuzzi G; Singh AK; Toto R; Huang F; Rossert J; McMurray JJ; Pfeffer MA;
N Engl J Med; 2010 Sep; 363(12):1146-55. PubMed ID: 20843249
[TBL] [Abstract][Full Text] [Related]
30. Erythropoietin: high profile, high scrutiny.
Crawford J
J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
[No Abstract] [Full Text] [Related]
31. Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease.
Agarwal AK
Expert Opin Drug Saf; 2009 Mar; 8(2):145-53. PubMed ID: 19309243
[TBL] [Abstract][Full Text] [Related]
32. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA).
Goldsmith D; Covic A
Nephrol Dial Transplant; 2010 Jun; 25(6):1734-7. PubMed ID: 20200007
[No Abstract] [Full Text] [Related]
33. Treatment of anemia with darbepoetin alfa in systolic heart failure.
Swedberg K; Young JB; Anand IS; Cheng S; Desai AS; Diaz R; Maggioni AP; McMurray JJ; O'Connor C; Pfeffer MA; Solomon SD; Sun Y; Tendera M; van Veldhuisen DJ; ;
N Engl J Med; 2013 Mar; 368(13):1210-9. PubMed ID: 23473338
[TBL] [Abstract][Full Text] [Related]
34. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B
BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887
[TBL] [Abstract][Full Text] [Related]
35. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
[TBL] [Abstract][Full Text] [Related]
36. Darbepoetin alfa and chronic kidney disease.
Hampl H; Kovesdy CP; Kalantar-Zadeh K
N Engl J Med; 2010 Feb; 362(7):654; author reply 655. PubMed ID: 20187260
[No Abstract] [Full Text] [Related]
37. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill J; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R; Uno H;
Am J Kidney Dis; 2009 Jul; 54(1):59-69. PubMed ID: 19501439
[TBL] [Abstract][Full Text] [Related]
38. Darbepoetin alfa and chronic kidney disease.
Minnerup J; Schäbitz WR
N Engl J Med; 2010 Feb; 362(7):653-4; author reply 655. PubMed ID: 20187258
[No Abstract] [Full Text] [Related]
39. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies.
Scott SD
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586
[TBL] [Abstract][Full Text] [Related]
40. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
Agarwal A; Silver MR; Walczyk M; Liu W; Audhya P
J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
